Brenner Randall B. 4
4 · Paratek Pharmaceuticals, Inc. · Filed Dec 15, 2021
Insider Transaction Report
Form 4
Brenner Randall B.
Chief Development & Regulatory
Transactions
- Sale
Common Stock
2021-12-15$4.27/sh−15,780$67,381→ 253,530 total - Sale
Common Stock
2021-12-13$4.42/sh−4,479$19,797→ 276,945 total - Sale
Common Stock
2021-12-14$4.37/sh−7,635$33,365→ 269,310 total
Footnotes (4)
- [F1]Sale of shares to cover personal income tax obligations upon vesting of restricted stock unit award, pursuant to a Rule 10b5-1 trading plan.
- [F2]The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions ranging from $4.31 to $4.52. The Reporting Person undertakes to provide to Paratek Pharmaceuticals, Inc., any security holder of Paratek Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote 2 to this Form 4.
- [F3]The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions ranging from $4.20 to $4.48. The Reporting Person undertakes to provide to Paratek Pharmaceuticals, Inc., any security holder of Paratek Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote 3 to this Form 4.
- [F4]The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions ranging from $4.11 to $4.34. The Reporting Person undertakes to provide to Paratek Pharmaceuticals, Inc., any security holder of Paratek Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote 4 to this Form 4.